U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT06874751) titled 'Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in the Real World' on March 08.
Brief Summary: This is a retrospective database study which includes administrative medical and pharmacy claims linked with clinical and laboratory measurements for patients in the US, to evaluate the effectiveness of once-weekly semaglutide 2.4 mg in reducing the risk of CV and other obesity-related clinical outcomes.
Study Start Date: Dec. 06, 2024
Study Type: OBSERVATIONAL
Condition:
Overweight
Obesity
Atherosclerotic Cardiovascular Disease (ASCVD)
Intervention:
OTHER: No treatment given
No treatment given
...